Fujian Taipingyang Pharmaceutical Co. Ltd.

Primary purpose: This study uses ibuprofen suspension (specification: 100 mL: 2g) developed by Fujian Pacific Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, ibuprofen suspension (trade name: Meilin®, specification: 100 mL: 2g) produced by the original research and development localization manufacturer Shanghai Johnson Pharmaceutical Co., Ltd. is used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: To observe the safety of the test preparation ibuprofen suspension and the reference preparation ibuprofen suspension (trade name: Meilin®) in healthy subjects.

Main objective: This study used ibuprofen sustained-release capsules (specification: 0.3 g) developed by Fujian Pacific Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, ibuprofen sustained-release capsules (specification: 0.3 g, trade name: Fenbid) produced by the original manufacturer Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd. were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions.